Related Experiment Video

Updated: May 8, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma

Masaomi Ikeda1, Tetsuo Fujita, Yasuyuki Amoh

  • 1Departments of Urology and Dermatology, Kitasato University School of Medicine, Sagamihara, Japan.

Urologia Internationalis
|August 24, 2013
PubMed

Insights

Sorafenib, a standard treatment for metastatic renal cell carcinoma, can cause skin toxicity. This report details the first known case of Stevens-Johnson syndrome, a severe skin reaction, linked to sorafenib therapy.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Sorafenib is a standard oral multikinase inhibitor for metastatic renal cell carcinoma (mRCC).
  • Skin toxicity, including hand-foot skin reaction, is a common adverse effect of sorafenib.
  • Severe mucocutaneous reactions like erythema multiforme are rare, and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have not been previously reported with sorafenib.

Observation:

  • This study reports the first documented case of Stevens-Johnson syndrome (SJS) in a patient treated with sorafenib.
  • The patient was receiving sorafenib for metastatic renal cell carcinoma.
  • The development of SJS represents a rare but severe adverse event associated with sorafenib.

Findings:

  • Sorafenib can induce severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS).
  • This case highlights the potential for sorafenib to cause rare, life-threatening dermatological conditions.
  • Early recognition and management of SJS are crucial in patients receiving sorafenib.

Implications:

  • Clinicians should be vigilant for severe skin reactions in patients treated with sorafenib for metastatic renal cell carcinoma.
  • This finding expands the known spectrum of sorafenib-induced toxicities.
  • Awareness of this rare adverse event is important for patient safety and treatment management.

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...